The risk of dying from the most common form of primary liver cancer is about 30 percent higher for patients with low household income compared to those with middle or high household income, according ...

Cancer of the liver, seen in a radial cross-section abdominal scan. (Photo by: BSIP/Universal Images Group via Getty Images) The number of new liver cancer cases will nearly double in the next 25 ...

Groundbreaking research and clinical trials are reshaping liver cancer treatment, especially hepatocellular carcinoma (HCC), with precision medicine and immunotherapy combinations leading the way.

A study presented at Digestive Disease Week 2016 found African American patients diagnosed with hepatocellular carcinoma had a 33 percent increased risk of death compared to non-Hispanic white ...

First-line nivolumab plus ipilimumab significantly improved survival versus lenvatinib or sorafenib in patients with unresectable liver cancer. The median overall survival of 23.7 months with the ...

In patients with unresectable liver cancer, treatment with Imjudo plus Imfinzi showed better survival outcomes compared with Nexavar. A treatment combination of Imjudo (tremelimumab) and Imfinzi ...

Survival rates for patients with hepatocellular carcinoma (HCC) have improved, but overall survival remains low. Early detection and treatment significantly enhanced survival outcomes between January ...

Immunotherapy-based combinations have rapidly replaced tyrosine kinase inhibitors as first-line treatment for advanced hepatocellular carcinoma, reshaping real-world practice over the past decade. In ...

UAB Medicine offers liver transplantation as a treatment for metastatic colorectal cancer, expanding access to advanced ...

Neoadjuvant ICIs in hepatocellular carcinoma may predict improved relapse-free survival post-resection, as shown in a large pooled analysis. Major pathological response was observed in 32% of patients ...